PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protalix BioTherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.56−0.06 (-2.29%)
Close on Oct 19, 2026
- Market cap
- $211.35M
- P/E (TTM)
- 11.1
- Dividend yield
- –
Protalix BioTherapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOODS | $53.61M | $49.23M | $51.80M | $61.27M | $61.44M | $59.30M | $52.98M | $44.93M | $37.26M | $39.03M | $40.42M | $34.38M | 66.5% | -12.7% |
| LICENSE AND R&D SERVICES | $27.01M | $27.16M | $942.00K | $571.00K | $513.00K | $465.00K | $418.00K | $738.00K | $795.00K | $20.63M | $25.08M | $29.25M | 33.5% | +5164.1% |
By region
From the segment and revenue-disaggregation notes of Protalix BioTherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.